PL3172227T3 - Cząsteczki, które selektywnie aktywują regulatorowe komórki T, do leczenia chorób autoimmunologicznych - Google Patents
Cząsteczki, które selektywnie aktywują regulatorowe komórki T, do leczenia chorób autoimmunologicznychInfo
- Publication number
- PL3172227T3 PL3172227T3 PL15824955T PL15824955T PL3172227T3 PL 3172227 T3 PL3172227 T3 PL 3172227T3 PL 15824955 T PL15824955 T PL 15824955T PL 15824955 T PL15824955 T PL 15824955T PL 3172227 T3 PL3172227 T3 PL 3172227T3
- Authority
- PL
- Poland
- Prior art keywords
- molecules
- cells
- treatment
- autoimmune diseases
- selectively activate
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 210000003289 regulatory T cell Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Marine Sciences & Fisheries (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461999241P | 2014-07-21 | 2014-07-21 | |
| EP15824955.7A EP3172227B9 (en) | 2014-07-21 | 2015-07-20 | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| PCT/US2015/041177 WO2016014428A2 (en) | 2014-07-21 | 2015-07-20 | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3172227T3 true PL3172227T3 (pl) | 2020-04-30 |
Family
ID=55163946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15824955T PL3172227T3 (pl) | 2014-07-21 | 2015-07-20 | Cząsteczki, które selektywnie aktywują regulatorowe komórki T, do leczenia chorób autoimmunologicznych |
Country Status (22)
| Country | Link |
|---|---|
| US (6) | US20170037102A1 (enExample) |
| EP (2) | EP3172227B9 (enExample) |
| JP (2) | JP6768633B2 (enExample) |
| KR (1) | KR102493543B1 (enExample) |
| CN (2) | CN106795213B (enExample) |
| AU (3) | AU2015292889C1 (enExample) |
| CA (1) | CA2954847A1 (enExample) |
| DK (1) | DK3172227T3 (enExample) |
| EA (2) | EA202190903A3 (enExample) |
| ES (1) | ES2763198T3 (enExample) |
| GB (1) | GB2538666A (enExample) |
| HU (1) | HUE046065T2 (enExample) |
| IL (3) | IL289475B2 (enExample) |
| LT (1) | LT3172227T (enExample) |
| MX (2) | MX378790B (enExample) |
| PL (1) | PL3172227T3 (enExample) |
| PT (1) | PT3172227T (enExample) |
| RS (1) | RS59789B1 (enExample) |
| SG (2) | SG10202010158TA (enExample) |
| SI (1) | SI3172227T1 (enExample) |
| WO (1) | WO2016014428A2 (enExample) |
| ZA (1) | ZA201700344B (enExample) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102208505B1 (ko) | 2012-12-11 | 2021-01-27 | 앨버트 아인슈타인 컬리지 오브 메디신 | 고처리량 수용체:리간드 확인을 위한 방법 |
| ES2763198T3 (es) * | 2014-07-21 | 2020-05-27 | Delinia Inc | Moléculas que selectivamente activan las células T reguladoras para el tratamiento de enfermedades autoinmunes |
| KR20170035910A (ko) | 2014-08-11 | 2017-03-31 | 데리니아, 인크. | 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 변형된 il-2 변이체 |
| CR20170510A (es) | 2015-04-10 | 2018-02-26 | Amgen Inc | Muteínas de interuquina 2 para la expansión de células t regulatorias |
| US20170204154A1 (en) * | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| NZ775714A (en) * | 2016-05-04 | 2024-12-20 | Amgen Inc | Interleukin-2 muteins for the expansion of t-regulatory cells |
| JP7071288B2 (ja) | 2016-05-18 | 2022-05-18 | キュー バイオファーマ， インコーポレイテッド | Ｔ細胞調節多量体ポリペプチド及びその使用方法 |
| US11339201B2 (en) | 2016-05-18 | 2022-05-24 | Albert Einstein College Of Medicine | Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof |
| CN110167957A (zh) * | 2016-11-08 | 2019-08-23 | 德里尼亚公司 | 用于治疗自身免疫疾病的il-2变体 |
| CN110177564A (zh) * | 2016-12-13 | 2019-08-27 | 德里尼亚公司 | 多价的调节t细胞调节剂 |
| US20190352363A1 (en) | 2016-12-22 | 2019-11-21 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| EP3565829A4 (en) | 2017-01-09 | 2021-01-27 | Cue Biopharma, Inc. | T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF |
| KR20190129077A (ko) | 2017-03-15 | 2019-11-19 | 팬디온 테라퓨틱스, 인코포레이티드 | 표적화된 면역관용 |
| IL309479A (en) | 2017-03-15 | 2024-02-01 | Cue Biopharma Inc | Methods for modulating an immune response |
| JP7001285B2 (ja) * | 2017-03-29 | 2022-01-19 | 国立大学法人 宮崎大学 | 長時間作用型アドレノメデュリン誘導体 |
| CA3064435A1 (en) | 2017-05-24 | 2018-11-29 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| PH12020550661A1 (en) | 2017-11-21 | 2021-04-19 | Univ Leland Stanford Junior | Partial agonists of interleukin-2 |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| BR112020011343A2 (pt) * | 2017-12-06 | 2020-11-17 | Pandion Therapeutics, Inc. | muteínas de il-2 e seus usos |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| MX2020006322A (es) | 2017-12-19 | 2020-09-18 | Xencor Inc | Proteinas de fusion il-2 fc modificadas. |
| WO2019131964A1 (ja) | 2017-12-27 | 2019-07-04 | 協和発酵キリン株式会社 | Ｉｌ－２改変体 |
| WO2019139896A1 (en) | 2018-01-09 | 2019-07-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| WO2019144309A1 (en) * | 2018-01-24 | 2019-08-01 | Beijing Percans Oncology Co. Ltd. | Cytokine Fusion Proteins |
| WO2019147837A2 (en) | 2018-01-24 | 2019-08-01 | Beijing Percans Oncology Co. Ltd. | Cytokine fusion proteins |
| EP3752178A1 (en) | 2018-02-16 | 2020-12-23 | Iltoo Pharma | Use of interleukin 2 for treating sjögren's syndrome |
| PE20210313A1 (es) | 2018-03-28 | 2021-02-12 | Bristol Myers Squibb Co | Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso |
| EP3552738B1 (en) * | 2018-04-12 | 2024-07-31 | Sandvik Machining Solutions AB | A method of producing an additive manufactured object |
| CN120349426A (zh) | 2018-06-22 | 2025-07-22 | 科优基因公司 | 白介素-2变体及其使用方法 |
| WO2020007937A1 (en) | 2018-07-03 | 2020-01-09 | Iltoo Pharma | Use of interleukin-2 for treating systemic sclerosis |
| JP2021530243A (ja) | 2018-07-25 | 2021-11-11 | アスクジーン・ファーマ・インコーポレイテッドAskGene Pharma, Inc. | 新規ｉｌ−２１プロドラッグおよびそれを使用する方法 |
| RU2021105821A (ru) | 2018-08-06 | 2021-05-27 | Медикайн, Инк. | Соединения, связывающие рецептор il-2 |
| WO2020035482A1 (en) | 2018-08-13 | 2020-02-20 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
| BR112021010983A2 (pt) * | 2018-12-21 | 2021-08-31 | Jiangsu Hengrui Medicine Co., Ltd. | Variante de interleucina-2 humana ou seu derivado |
| MX2021008958A (es) | 2019-02-01 | 2021-11-04 | Regeneron Pharma | Proteínas de unión a antígeno del receptor gamma anti-il2. |
| JP7570338B2 (ja) | 2019-02-15 | 2024-10-21 | インテグラル・モレキュラー・インコーポレイテッド | クローディン６抗体及びその使用 |
| US11254736B2 (en) | 2019-02-15 | 2022-02-22 | Integral Molecular, Inc. | Antibodies comprising a common light chain and uses thereof |
| TW202110885A (zh) | 2019-05-20 | 2021-03-16 | 美商潘迪恩治療公司 | 靶向ＭＡｄＣＡＭ之免疫耐受性 |
| KR20220020879A (ko) | 2019-06-12 | 2022-02-21 | 에스크진 파마, 아이엔씨. | 새로운 il-15 프로드럭 및 이를 사용하는 방법 |
| BR112022001415A2 (pt) | 2019-07-26 | 2022-06-07 | Visterra Inc | Agentes interleucina-2 e os usos dos mesmos |
| JP7690458B2 (ja) * | 2019-08-12 | 2025-06-10 | アスクジーン・ファーマ・インコーポレイテッド | 優先的にｉｌ－２ｒアルファに結合するｉｌ－２融合タンパク質 |
| BR112022008744A2 (pt) | 2019-11-05 | 2022-07-19 | Medikine Inc | Ligante de il-2rss, ligante de il-2r¿c, composto de ligação a il-2r¿¿c, composição farmacêutica, método para tratar uma doença em um paciente, método para expandir células imunes, método de uma terapia celular, método para reforçar uma vacina, método para modificar a resposta imune e ácido nucleico |
| KR20220110209A (ko) | 2019-11-05 | 2022-08-05 | 메디카인 인코포레이티드 | 이중 il-2r 및 il-7r 결합 화합물 |
| WO2021116444A1 (en) | 2019-12-12 | 2021-06-17 | Iltoo Pharma | Interleukin 2 chimeric constructs |
| US12091440B2 (en) | 2019-12-20 | 2024-09-17 | Regeneron Pharmaceuticals, Inc. | IL2 and peptide-MHC complex fusion proteins and methods of use thereof |
| MX2022008771A (es) | 2020-01-14 | 2022-10-07 | Synthekine Inc | Metodos y composiciones de muteinas de il2 sesgadas. |
| MX2022009302A (es) | 2020-02-03 | 2022-11-16 | Medikine Inc | Compuestos de unión a il-7r¿. |
| WO2021158623A1 (en) | 2020-02-03 | 2021-08-12 | Medikine, Inc. | IL-7Rαγc BINDING COMPOUNDS |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| US11028132B1 (en) | 2020-04-07 | 2021-06-08 | Yitzhak Rosen | Half-life optimized linker composition |
| CA3169949A1 (en) | 2020-05-12 | 2021-11-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| JP2023526282A (ja) | 2020-05-13 | 2023-06-21 | ボナム セラピューティクス，インク． | タンパク質複合体の組成物及びその使用方法 |
| KR20230060514A (ko) * | 2020-09-01 | 2023-05-04 | 다케다 야쿠힌 고교 가부시키가이샤 | 인터루킨-2 뮤테인 및 이의 용도 |
| JP2023541366A (ja) | 2020-09-09 | 2023-10-02 | キュー バイオファーマ， インコーポレイテッド | １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法 |
| TW202233673A (zh) | 2020-10-23 | 2022-09-01 | 美商雅雪生物治療公司 | 含調節免疫細胞功能之ｃｄ８抗原結合分子之融合物 |
| JP2023548311A (ja) | 2020-10-29 | 2023-11-16 | ブリストル－マイヤーズ スクイブ カンパニー | 疾患の治療のための融合タンパク質 |
| JP2023549191A (ja) | 2020-11-13 | 2023-11-22 | 江蘇恒瑞医薬股▲ふん▼有限公司 | ヒトインターロイキン２の変異体又はその誘導体を含む医薬組成物及びその用途 |
| JP2024502708A (ja) | 2020-12-04 | 2024-01-23 | ビステラ， インコーポレイテッド | インターロイキン－２作用物質を使用する方法 |
| IL304365B2 (en) * | 2021-03-31 | 2025-04-01 | Hanmi Pharmaceutical Co Ltd | A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof |
| BR112023020597A2 (pt) | 2021-04-09 | 2023-12-12 | Selecta Biosciences Inc | Nanocarreadores sintéticos que compreendem um imunossupressante em combinação com agonistas do receptor de il-2 de alta afinidade para aumentar a tolerância imune |
| EP4412631A1 (en) | 2021-10-06 | 2024-08-14 | Iltoo Pharma | Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| US20230263906A1 (en) | 2022-01-10 | 2023-08-24 | Selecta Biosciences, Inc. | High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing |
| US20230322884A1 (en) | 2022-03-09 | 2023-10-12 | Selecta Biosciences, Inc. | Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing |
| WO2023183568A1 (en) | 2022-03-25 | 2023-09-28 | Selecta Biosciences, Inc. | Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists and anti-igm agents |
| US20250222027A1 (en) | 2022-04-01 | 2025-07-10 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| US11999771B2 (en) | 2022-04-07 | 2024-06-04 | Medikine, Inc. | IL-7Rαγc ligand immunoglobulin fusion proteins |
| WO2023196566A1 (en) | 2022-04-08 | 2023-10-12 | Selecta Biosciences, Inc. | High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance |
| AU2022477937A1 (en) | 2022-09-12 | 2025-04-10 | Assistance Publique - Hôpitaux De Paris | Interleukin-2 for use in treating autism spectrum disorder |
| US12049502B2 (en) | 2022-11-30 | 2024-07-30 | Integral Molecular, Inc. | Antibodies directed to claudin 6, including bispecific formats thereof |
| EP4648792A2 (en) | 2023-01-09 | 2025-11-19 | Odyssey Therapeutics, Inc. | Anti-tnfr2 antigen-binding proteins and uses thereof |
| WO2024229370A1 (en) | 2023-05-03 | 2024-11-07 | Cartesian Therapeutics, Inc. | Compositions and methods for treating gvhd |
| WO2024229350A1 (en) | 2023-05-03 | 2024-11-07 | Cartesian Therapeutics, Inc. | Immunosuppressant in combination with high affinity il-2 receptor agonists for diabetes |
| WO2024229380A1 (en) | 2023-05-03 | 2024-11-07 | Cartesian Therapeutics, Inc. | Immunosuppressant in combination with high affinity il-2 receptor agonists in autoimmune liver diseases |
| WO2024229432A1 (en) | 2023-05-03 | 2024-11-07 | Cartesian Therapeutics, Inc. | Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance |
| WO2025217240A1 (en) | 2024-04-10 | 2025-10-16 | Odyssey Therapeutics, Inc. | Anti-tnfr2 antigen-binding proteins and uses thereof |
| WO2026006809A1 (en) | 2024-06-27 | 2026-01-02 | Odyssey Therapeutics, Inc. | Multispecific molecules binding tnfr2 and cd25 and uses thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6541610B1 (en) * | 1989-09-05 | 2003-04-01 | Immunex Corporation | Fusion proteins comprising tumor necrosis factor receptor |
| US6955807B1 (en) | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
| EP1421187B1 (en) | 2001-07-27 | 2007-10-10 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Systems for in vivo site-directed mutagenesis using oligonucleotides |
| ATE542137T1 (de) * | 2001-12-04 | 2012-02-15 | Merck Patent Gmbh | Immunocytokine mit modulierter selektivität |
| KR100758755B1 (ko) | 2003-06-12 | 2007-09-14 | 일라이 릴리 앤드 캄파니 | Ｇｌｐ-1 유사체 융합 단백질 |
| ES2383328T3 (es) * | 2003-07-25 | 2012-06-20 | Amgen, Inc | Métodos relacionados con LDCAM y CRTAM |
| CN1930300A (zh) * | 2004-03-05 | 2007-03-14 | 希龙公司 | 预测患者治疗药物耐受性的体外试验系统 |
| BRPI0508470A (pt) * | 2004-03-05 | 2007-07-31 | Chiron Corp | sistema de teste in vitro para prever toleráncia do paciente aos agentes terapêuticos |
| CA2656700A1 (en) * | 2006-07-06 | 2008-01-10 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Compositions and methods for enhancing the efficacy of il-2 mediated immune responses |
| PL2066694T3 (pl) * | 2006-09-29 | 2016-04-29 | Oncomed Pharm Inc | Kompozycje i sposoby diagnozowania i leczenia nowotworu |
| WO2010085495A1 (en) * | 2009-01-21 | 2010-07-29 | Amgen Inc. | Compositions and methods of treating inflammatory and autoimmune diseases |
| KR20150036824A (ko) * | 2009-03-20 | 2015-04-07 | 제넨테크, 인크. | 이중특이적 항-ｈｅｒ 항체 |
| DK2542590T4 (da) * | 2010-03-05 | 2020-07-13 | Univ Johns Hopkins | Sammensætninger og fremgangsmåde til målrettede immunomodulatoriske antistof-fer og fusionproteiner |
| CN102174111B (zh) * | 2011-01-25 | 2013-01-09 | 江苏省弗泰生物科技有限公司 | 人白介素2-Fc融合蛋白及其用途 |
| SG10201604160WA (en) * | 2011-02-10 | 2016-07-28 | Roche Glycart Ag | Mutant Interleukin-2 Polypeptides |
| EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| JP2014094898A (ja) * | 2012-11-07 | 2014-05-22 | Univ Of Tsukuba | 炎症性腸疾患に関連する、ＣＤ３００ａ発現細胞の活性調節剤を含有する医薬品、ならびにＣＤ３００ａ遺伝子欠損マウスおよびＣＤ３００ａ発現細胞の活性調節剤の使用 |
| US9580486B2 (en) | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
| CA2906927C (en) * | 2013-03-15 | 2021-07-13 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| CN103193887B (zh) * | 2013-04-03 | 2015-02-04 | 江苏众红生物工程创药研究院有限公司 | 一种重组猪白细胞介素2-Fc融合蛋白及其编码基因和表达方法 |
| ES2763198T3 (es) * | 2014-07-21 | 2020-05-27 | Delinia Inc | Moléculas que selectivamente activan las células T reguladoras para el tratamiento de enfermedades autoinmunes |
| US20170204154A1 (en) * | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
-
2015
- 2015-07-20 ES ES15824955T patent/ES2763198T3/es active Active
- 2015-07-20 GB GB1615553.3A patent/GB2538666A/en not_active Withdrawn
- 2015-07-20 SG SG10202010158TA patent/SG10202010158TA/en unknown
- 2015-07-20 WO PCT/US2015/041177 patent/WO2016014428A2/en not_active Ceased
- 2015-07-20 SI SI201530968T patent/SI3172227T1/sl unknown
- 2015-07-20 RS RS20191448A patent/RS59789B1/sr unknown
- 2015-07-20 EA EA202190903A patent/EA202190903A3/ru unknown
- 2015-07-20 CN CN201580050979.6A patent/CN106795213B/zh not_active Expired - Fee Related
- 2015-07-20 CA CA2954847A patent/CA2954847A1/en active Pending
- 2015-07-20 PT PT158249557T patent/PT3172227T/pt unknown
- 2015-07-20 JP JP2017504096A patent/JP6768633B2/ja not_active Expired - Fee Related
- 2015-07-20 EP EP15824955.7A patent/EP3172227B9/en active Active
- 2015-07-20 IL IL289475A patent/IL289475B2/en unknown
- 2015-07-20 AU AU2015292889A patent/AU2015292889C1/en not_active Withdrawn - After Issue
- 2015-07-20 DK DK15824955T patent/DK3172227T3/da active
- 2015-07-20 SG SG11201700514SA patent/SG11201700514SA/en unknown
- 2015-07-20 HU HUE15824955A patent/HUE046065T2/hu unknown
- 2015-07-20 CN CN202111371055.XA patent/CN114133456A/zh active Pending
- 2015-07-20 MX MX2017000821A patent/MX378790B/es unknown
- 2015-07-20 EP EP19188596.1A patent/EP3587444A1/en not_active Withdrawn
- 2015-07-20 KR KR1020177001922A patent/KR102493543B1/ko active Active
- 2015-07-20 PL PL15824955T patent/PL3172227T3/pl unknown
- 2015-07-20 EA EA201790213A patent/EA038361B1/ru unknown
- 2015-07-20 LT LTEP15824955.7T patent/LT3172227T/lt unknown
-
2016
- 2016-09-14 US US15/265,764 patent/US20170037102A1/en not_active Abandoned
- 2016-09-14 US US15/265,770 patent/US20170051029A1/en not_active Abandoned
-
2017
- 2017-01-10 IL IL250024A patent/IL250024B/en active IP Right Grant
- 2017-01-16 ZA ZA2017/00344A patent/ZA201700344B/en unknown
- 2017-01-18 MX MX2021000083A patent/MX2021000083A/es unknown
- 2017-07-28 US US15/662,633 patent/US20170327555A1/en not_active Abandoned
-
2019
- 2019-01-17 US US16/250,255 patent/US20190375812A1/en not_active Abandoned
-
2020
- 2020-04-07 US US16/841,815 patent/US20210047382A1/en not_active Abandoned
- 2020-05-27 AU AU2020203480A patent/AU2020203480A1/en not_active Abandoned
- 2020-09-02 JP JP2020147441A patent/JP2021006038A/ja active Pending
- 2020-10-26 IL IL278299A patent/IL278299B/en unknown
-
2021
- 2021-12-20 US US17/556,208 patent/US20220112260A1/en not_active Abandoned
-
2022
- 2022-07-11 AU AU2022204946A patent/AU2022204946A1/en not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289475A (en) | Molecules that activate t cells are selectively regulated for the treatment of autoimmune diseases | |
| ZA201804458B (en) | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases | |
| ZA201700381B (en) | Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases | |
| SG11201609770TA (en) | Combination therapies for the treatment of cancer | |
| IL259281B (en) | History of bipyrazolyl used in the treatment of autoimmune diseases | |
| SI3122358T1 (sl) | Kombinacije FGFR- in CMET-inhibitorjev za zdravljenje raka | |
| PL3277280T3 (pl) | Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych | |
| IL259486A (en) | Agents for the treatment of diseases associated with undesired cell proliferation | |
| PL3129483T3 (pl) | Terapia skojarzona do leczenia chorób autoimmunologicznych | |
| IL249710A0 (en) | Wastewater treatment system | |
| PL3012014T3 (pl) | Instalacja obróbki płynu | |
| GB201411027D0 (en) | Treatment | |
| GB201414023D0 (en) | Treatment of autoimmune diseases | |
| ZA201403183B (en) | Effluent treatment system | |
| GB201412441D0 (en) | Treatment system | |
| GB201412410D0 (en) | Treatment | |
| GB201400241D0 (en) | Treatment | |
| GB201400235D0 (en) | Treatment | |
| GB201400240D0 (en) | Treatment | |
| GB201400239D0 (en) | Treatment | |
| GB201400238D0 (en) | Treatment |